Bausch Health Rises From Valeant's Simmering Ashes
Valeant will change its name to Bausch Health beginning in July and get a new ticker symbol, BHC, as the new management team looks to leave the company's checkered past behind.
You may also be interested in...
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
With dermatologists reporting issues with prior authorization requirements, Ortho Derm is offering several reduced-price products under a new cash-pay format.
The company reported a second quarter of organic sales growth, though revenues declined because of divestitures. Dermatology and Diversified Products segments continued to face challenges, and the company is working to respond to an FDA CRL for potential new dermatology product Duobrii.